Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,024,100 | 727,200 | 4,504,900 | 3,660,300 | 2,200,300 |
| Depreciation Amortization | 246,900 | 123,200 | 543,700 | 398,700 | 262,000 |
| Income taxes - deferred | -290,400 | -96,000 | -785,400 | -552,900 | -274,300 |
| Accounts receivable | -837,300 | 1,200 | 498,100 | 549,300 | 629,600 |
| Other Working Capital | -612,700 | 36,500 | 532,600 | 526,700 | -98,300 |
| Other Operating Activity | 1,361,300 | 286,800 | -315,000 | -773,900 | -529,800 |
| Operating Cash Flow | $1,891,900 | $1,078,900 | $4,978,900 | $3,808,200 | $2,189,500 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 49,100 | -149,400 | 587,900 | 76,600 | 231,800 |
| PPE Investments | -470,800 | -230,600 | -898,400 | -649,700 | -448,300 |
| Net Acquisitions | N/A | N/A | -3,300 | -3,000 | N/A |
| Purchase Sale Intangibles | -99,900 | -48,900 | -315,300 | -273,300 | -230,000 |
| Other Investing Activity | -99,900 | -48,900 | -315,300 | -273,300 | -230,000 |
| Investing Cash Flow | $-521,600 | $-428,900 | $-629,100 | $-849,400 | $-446,500 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 212,300 | 163,100 | 635,900 | 132,400 | 92,100 |
| Common Stock Repurchased | -2,044,500 | -867,500 | -3,970,700 | -2,779,800 | -2,112,800 |
| Dividend Paid | -194,600 | -97,800 | -370,300 | -277,600 | -186,400 |
| Other Financing Activity | 0 | 0 | -10,300 | -10,300 | -10,300 |
| Financing Cash Flow | $-2,026,800 | $-802,200 | $-3,715,400 | $-2,935,300 | $-2,217,400 |
| Exchange Rate Effect | -1,200 | -900 | 300 | 600 | 1,000 |
| Beginning Cash Position | 3,123,700 | 3,123,700 | 2,489,000 | 2,489,000 | 2,489,000 |
| End Cash Position | 2,466,000 | 2,970,600 | 3,123,700 | 2,513,100 | 2,015,600 |
| Net Cash Flow | $-657,700 | $-153,100 | $634,700 | $24,100 | $-473,400 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,891,900 | 1,078,900 | 4,978,900 | 3,808,200 | 2,189,500 |
| Capital Expenditure | -470,800 | -230,600 | -898,400 | -649,700 | -448,300 |
| Free Cash Flow | 1,421,100 | 848,300 | 4,080,500 | 3,158,500 | 1,741,200 |